Table 1 Cytoreductive rates and overall survival with a primary surgery approach in the management of advanced ovarian carcinoma published by different authors
From: How to improve the optimal cytoreductive surgery in advanced ovarian carcinoma
Article | Year | Number | FIGO stage | Cytoreduction rate | OS (months) |
|---|---|---|---|---|---|
Eisenkop [19] | 1992 | 250 | IIIC–IV | Complete, 11.2% | >60 |
<1 cm, 43.6% | 32 | ||||
>1 cm, 42.5% | 16 | ||||
Makar [6] | 1995 | 455 | IIIA, B, C | Complete, 9.9% | 75 |
<2 cm, 17% | 45 | ||||
>2 cm, 73% | 18 | ||||
Le [20] | 1997 | 330 | IIIA, B, C | Complete, 15.4% | 54 |
<2 cm, 27.0% | 21 | ||||
>2 cm, 57% | 16 | ||||
Ozols [2] | 2003 | 792 | IIIA, B, C | Complete, 35.5% | 60 |
≤1 cm, 64.5% | 38 | ||||
Eisenkop [21] | 2003 | 408 | IIIC | Complete, 86.0% | 76 |
≤1 cm, 10.0% | 32 | ||||
>1 cm, 4% | 16 | ||||
Aletti [9] | 2006 | 194 | IIIC | Complete, 23.7% | 80 |
<1 cm, 43% | 38 | ||||
1–2 cm, 11.3% | 22 | ||||
>2 cm, 21.1% | 16 | ||||
Chi [22] | 2006 | 465 | IIIC | Complete, 14.7% | 106 |
<0.5 cm, 15.1% | 66 | ||||
0.6–1 cm, 21.3% | 48 | ||||
1–2 cm, 11.4% | 33 | ||||
>2 cm, 37.8% | 34 | ||||
Du Bois [23] | 2009 | 3126 | IIIC | Complete, 33.4% | 99 |
<1 cm, 31.2% | 36 | ||||
>1 cm, 35.4% | 29 | ||||
Vergote [24] | 2010 | 310 | IIIC–IV | Complete | 45 |
<1 cm | 32 | ||||
>1 cm | 26 |